A novel monoclonal antibody against beta-amyloid (Abeta) peptide is provided with unique immunological and biological properties useful in the immunotherapy of Alzheimers disease. In addition, pharmaceutical compositions and kits comprising such antibody and mimics thereof in the treatment of neurological disorders such as Alzheimers disease are described.